Dr. William Kim, MD

• Orthopedic Surgery

• Hip & Knee Orthopedics

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of California Los Angeles

  Fellowship Hospital

• Case Western Reserve University

  Residency Hospital

• Gundersen Clin/luth Hospital

  Internship Hospital

• University Of California-los Angeles

  Fellowship Hospital, 1982

• University Of Iowa Carver College Of Medicine

  Medical School, 1974

• California Orthopaedic Association, Member

• English

• Spanish

• Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss, 2020-02-04

• Stearoyl Co-A Desaturase 1 as a ccRCC Therapeutic Target: Death by Stress, 2013-05-24

• MYCactivation cooperates withVhlandInk4a/Arfloss to induce clear cell renal cell carcinoma, 2017-06-08

• VHL Substrate Transcription Factor ZHX2 As An Oncogenic Driver In Clear Cell Renal Cell Carcinoma, 2018-07-20

• Development and validation of a NanoString BASE47 bladder cancer gene classifier, 2020-12-17

• Viewing RCC with a DNA methylation lens ENHANCES understanding of ICI resistance, 2023-04-03

• Drug Efficacy Testing in Mice, 2013-07-10

• Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset, 2017-03-30

• Identification of Novel Gene Targets and Putative Regulators of Arsenic-Associated DNA Methylation in Human Urothelial Cells and Bladder Cancer, 2015-06-03

• Systemic Delivery of Gemcitabine Triphosphate via LCP Nanoparticles for NSCLC and Pancreatic Cancer Therapy, 2013-02-04

• Racial disparities in survival in advanced renal cell carcinoma in the targeted therapy era, 2016-06-24

• Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer, 2022-11-04

• Roadmap for the Development of the University of North Carolina at Chapel Hill G enitourinary O nco L ogy D atabase - UNC GOLD, 2013-02-19

• PBRM1 inactivation promotes upregulation of human endogenous retroviruses in a HIF-dependent manner, 2022-03-01

• mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma, 2014-09-02

• Pparg signaling controls bladder cancer subtype and immune exclusion, 2021-10-25

• Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings, 2015-06-27

• Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model, 2014-03-15

• LOSS OF JAK2 REGULATION VIA VHL-SOCS1 E3 UBIQUITIN HETEROCOMPLEX UNDERLIES CHUVASH POLYCYTHEMIA, 2011-06-19

• Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis, 2014-11-04

• Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy, 2018-10-08

• A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients, 2010-07-01

• Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays, 2018-06-04

• Identification of a novel inflamed tumor microenvironment signature as a predictive biomarker of bacillus Calmette-Guerin immunotherapy in non-muscle invasive bladder cancer, 2021-06-11

• Integrative genomic and proteomic analyses identify targets forLkb1deficient metastatic lung tumors, 2010-06-15

• Trends in Stage-Specific Incidence Rates for Urothelial Carcinoma of the Bladder in the United States: 1988 to 2006, 2013-10-10

• Comprehensive Molecular Characterization of Papillary Renal Cell Carcinoma, 2015-11-04

• Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors, 2018-03-07

• Correction to: Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience, 2022-03-11

• MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression, 2019-04-03

• Quaking Orchestrates a Post-Transcriptional Regulatory Network of Endothelial Cell Cycle Progression Critical to Angiogenesis and Metastasis, 2019-03-27

• Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy, 2018-05-21

• The Cancer/Testes (CT) Antigen HORMAD1 promotes Homologous Recombinational DNA Repair and Radioresistance in Lung adenocarcinoma cells, 2018-10-17

• Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer, 2014-08-22

• Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signaling, 2015-01-27

• Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a target inLKB1Mutant Lung Cancer, 2013-05-28

• Dynamic Reprogramming of the Kinome In Response to Targeted MEK Inhibition In Triple Negative Breast Cancer, 2012-04-13

• The Binding Site Barrier Elicited by Tumor-Associated Fibroblasts Interferes Disposition of Nanoparticles in Stroma-Vessel Type Tumors, 2016-09-28

• Age at Diagnosis, Obesity, Smoking, and Molecular Subtypes in Muscle Invasive Bladder Cancer, 2017-03-20